[ CAS No. 7693-46-1 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

2D 3D

Structure of 7693-46-1 * Storage: {[proInfo.prStorage]}

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	Inquiry	{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price) ]}	{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]}	{[ item.pr_usastock ]}		{[ item.pr_chinastock ]}	{[ item.pr_remark ]}	Login		Inquiry

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

For Research Only 120K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 7693-46-1 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 7693-46-1 ]

SDS Specification

Alternatived Products of [ 7693-46-1 ]

Product Citations Expand+

Folate-conjugated organic CO prodrugs: Synthesis and CO release kinetic studies

Shameer M. Kondengadan ; Shubham Bansal ; Xiaoxiao Yang , et al. Research Square,2024. DOI: 10.21203/rs.3.rs-4213303/v1

Abstract: Carbon monoxide (CO) is an endogenous produced molecule and has shown efficacy in animal models of inflammation, organ injury, colitis and cancer metastasis. Because of its gaseous nature, there is a need for developing efficient CO delivery approaches, especially those capable of targeted delivery. In this study, we aim to take advantage of a previously reported approach of enrichment-triggered prodrug activation to achieve targeted delivery by targeting the folate receptor. The general idea is to exploit folate receptor-mediated enrichment as a way to accelerate a biomolecular Diels-Alder reaction for prodrug activation. In doing so, we first need to find ways to tune the reaction kinetics in order to ensure minimal rection without enrichment and optimal activation upon enrichment. In this feasibility study, we synthesized two diene-dienophile pairs and studied their reaction kinetics and ability to target the folate receptor. We found that folate conjugation significantly affects the reaction kinetics of the original diene-dienophile pairs. Such information will be very useful in future designs of similar targeted approaches of CO delivery.

Keywords: Enrichment triggered delivery ; Carbon Monoxide ; Folate conjugate ; Reaction kinetics ; Diels-Alder reaction

Purchased from AmBeed: 7693-46-1 ; 59-30-3 ; 57260-73-8 ; 74426-51-0

Novel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders

Raithatha, Sheetal A. ; Hagel, Jillian M. ; Matinkhoo, Kaveh , et al. J. Med. Chem.,2023, 67(2): 1024-1043. DOI: 10.1021/acs.jmedchem.3c01225 PubMed ID: 37983270

Abstract: The psychedelic prodrug psilocybin has shown therapeutic benefits for the treatment of numerous psychiatric conditions. Despite pos. clin. end points targeting depression and anxiety, concerns regarding the duration of the psychedelic experience produced by psilocybin, associated with enduring systemic exposure to the active metabolite psilocin, pose a barrier to its therapeutic application. Our objective was to create a novel prodrug of psilocin with similar therapeutic benefits but a reduced duration of psychedelic effects compared with psilocybin. Here, we report the synthesis and functional screening of 28 new chem. entities. Our strategy was to introduce a diversity of cleavable groups at the 4-hydroxy position of the core indole moiety to modulate metabolic processing. We identified several novel prodrugs of psilocin with altered pharmacokinetic profiles and reduced pharmacol. exposure compared with psilocybin. These candidate prodrugs have the potential to maintain the long term benefits of psilocybin therapy while attenuating the duration of psychedelic effects.

Purchased from AmBeed: 7693-46-1 ; 33657-49-7 ; 38871-41-9 ; 20289-26-3 ; 2251-50-5 ; 35180-01-9 ; 4090-55-5 ; 54322-65-5 ; 77877-94-2 ; 52061-51-5 ; 63881-16-3 ; 5402-53-9 ; 7693-46-1

Product Details of [ 7693-46-1 ]

CAS No. :	7693-46-1	MDL No. :	MFCD00007321
Formula :	C₇H₄ClNO₄	Boiling Point :	-
Linear Structure Formula :	O₂NC₆H₄OC(O)Cl	InChI Key :	NXLNNXIXOYSCMB-UHFFFAOYSA-N
M.W :	201.56	Pubchem ID :	82129
Synonyms :

Calculated chemistry of [ 7693-46-1 ] Expand+

Physicochemical Properties

Num. heavy atoms :	13
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.0
Num. rotatable bonds :	3
Num. H-bond acceptors :	4.0
Num. H-bond donors :	0.0
Molar Refractivity :	47.14
TPSA :	72.12 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-5.71 cm/s

Lipophilicity

Log Po/w (iLOGP) :	1.36
Log Po/w (XLOGP3) :	2.56
Log Po/w (WLOGP) :	2.33
Log Po/w (MLOGP) :	0.84
Log Po/w (SILICOS-IT) :	-0.24
Consensus Log Po/w :	1.37

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-2.85
Solubility :	0.287 mg/ml ; 0.00143 mol/l
Class :	Soluble
Log S (Ali) :	-3.72
Solubility :	0.0382 mg/ml ; 0.00019 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-2.09
Solubility :	1.64 mg/ml ; 0.00815 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	3.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.82

Safety of [ 7693-46-1 ]

Signal Word:	Danger	Class:	8
Precautionary Statements:	P261-P280-P305+P351+P338-P310	UN#:	3261
Hazard Statements:	H314-H335	Packing Group:	Ⅱ
GHS Pictogram:

Application In Synthesis of [ 7693-46-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 7693-46-1 ]

[ 7693-46-1 ] Synthesis Path-Downstream 1~13

1
[ 3743-22-4 ]
[ 7693-46-1 ]
[ 77648-78-3 ]

Reference： [1]Journal of the American Chemical Society,1981,vol. 103,p. 4194 - 4199

2
[ 2580-77-0 ]
[ 7693-46-1 ]
[ 57772-67-5 ]

Reference： [1]Nucleosides, nucleotides and nucleic acids,2005,vol. 24,p. 211 - 226
[2]Chemical Science,2018,vol. 9,p. 8388 - 8395

3
[ 7693-46-1 ]
[ 97682-44-5 ]

Reference： [1]Chemistry - A European Journal,1998,vol. 4,p. 67 - 83

4
[ 25475-67-6 ]
[ 919278-09-4 ]
[ 7693-46-1 ]
N-{2-chloro-4-[(5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)oxy]phenyl}-N'-isoquinolin-3-ylurea [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
16%	With pyridine; In ISOPROPYLAMIDE; at 90℃; for 18h;	To a solution of <strong>[25475-67-6]3-aminoisoquinoline</strong> (210 mg, 1.5 mmol), EPO <DP n="223"/>pyridine (236 muL, 2.9 mmol) and 4-nitrophenyl chlorocarbonate (294 mg, 1.5 mmol) in N,N-dimethylacetamide (6 mL) was added 2-chloro-4- [ (5-methyl-5H-pyrrolo [3, 2-d] pyrimidin-4- yl) oxy]"aniline (200 mg, 0.73 mmol), and the mixture was stirred at 900C for 18 hr. The reaction mixture was diluted with water, and extracted with ethyl acetate (chil) . The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and filtrated. The filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography (NH silica gel, ethyl acetate) and recrystallized from ethyl acetate-hexane to give the title compound (53 mg, 16percent) as a colorless solid.1H-NMR (DMSO-de, 300 MHz) delta 4.11 (3H, s) , 6.61 (IH, d, J = 3.0 Hz), 7.30 - 8.40 (1OH, m) , 9.19 (IH, -s) , 10.08 (IH, s) .

Reference： [1]Patent: WO2007/4749,2007,A1 .Location in patent: Page/Page column 221-222

5
[ 7693-46-1 ]
[ 302348-51-2 ]
[ 1254765-89-3 ]

Yield	Reaction Conditions	Operation in experiment
80%		To a solution of 4-nitrophenyl chloroformate (264 mg, 1.26 mmol) in 3 mL of DCM at 0 C was added dropwise Et3N (177 muL, 1.26 mmol). The mixture was stirred during 20 min under argon then a solution of 6a (100 mg, 0.42 mmol) in 4 mL of DCM was added dropwise to the first solution and the mixture was stirred during 3 h at r.t. The reaction was quenched with brine, extracted with DCM (3×20 mL), the organic layers were combined, dried with MgSO4 and concentrated under reduced pressure to give a crude product. The crude product was purified by column chromatography over silica gel with cyclohexane-EtOAc: 90- 10 to 60-40 to give the expected product (135 mg, yield: 80%). 1H NMR (300 MHz, CDCl3) delta 7.88-7.82 (m, 2H), 7.46-7.41 (m, 2H), 7.40-7.35 (m, 2H), 5.31 (m, 2H), 1.35 (s, 12H). 13C NMR (75 MHz, CDCl3) delta 155.47, 152.38, 145.36, 137.02, 135.15, 127.58, 127.23, 125.25, 121.74, 83.95, 70.75, 24.82. HRMS (ESI): m/z Calcd for C20H22BNO7Na, [M+Na]+:422.1387, found: 422.1367.
60%	With triethylamine; In tetrahydrofuran; at 20℃; for 1h;Product distribution / selectivity;	4-(Hydroxymethyl)phenylboronic acid pinacol ester (0.5 g, 2.1 mmol) was dissolved in 20 mL of dry THF. Triethylamine (0.6 mL, 4.3 mmol) was added followed by 4-nitrophenyl chloroformate (0.47 g, 2.3 mmol) and the reaction was allowed to stir at room temperature for 1 h. The reaction was diluted with EtOAc and washed with 1.0 M HCl followed by saturated NaHCO3. The organic layer was dried over MgSO4, filtered and concentrated. Compound B2a was purified on a silica gel column eluting with 5% EtOAc in hexanes to give 0.51 g (1.3 mmol, 60% yield) as a white solid. 1H NMR (400 MHz, CDCl3) delta=8.25 (d, J=9.2 Hz, 2H), 7.85 (d, J=8.0 Hz, 2H), 7.43 (d, J=8.0 Hz, 2H), 7.36 (d, J=9.2 Hz, 2H), 5.31 (s, 2H), 1.35 (s, 12H). 13C NMR (100 MHz, CDCl3) delta=155.7, 152.7, 145.6, 137.2, 135.4, 127.9, 125.5, 122.0, 84.2, 71.0, 25.1. ESI-MS(+): m/z 417.19 [M+NH4]+, 422.20 [M+Na]+.
	In dichloromethane; at 0℃;	1) Preparation of active small molecules:Mixing 4-(hydroxymethyl)phenylboronic acid pinacol ester and p-nitrophenoxycarbonyl chloride as a molar ratio of 1:1The solution was dissolved in dichloromethane in that order, and the reaction was stirred well at 0 C.Synthesizing a small molecule capable of reversibly binding to methotrexate;

Reference： [1]Organic and Biomolecular Chemistry,2014,vol. 12,p. 5435 - 5441
[2]Bioorganic Chemistry,2019,vol. 91
[3]Journal of the American Chemical Society,2018,vol. 140,p. 6109 - 6121
[4]Angewandte Chemie - International Edition,2010,vol. 49,p. 6795 - 6797
[5]Chemical Communications,2011,vol. 47,p. 7968 - 7970
[6]Patent: US2011/312905,2011,A1 .Location in patent: Page/Page column 39
[7]Journal of the American Chemical Society,2019,vol. 141,p. 4073 - 4079
[8]Patent: CN110156823,2019,A .Location in patent: Paragraph 0023-0025; 0027-0029

6
[ 1334041-91-6 ]
[ 33024-60-1 ]
[ 7693-46-1 ]
[ 1334041-63-2 ]

Yield	Reaction Conditions	Operation in experiment
49%		Procedure: 4-Nitrophenyl chloroformate (43 mg, 0.216 mmol) was added to DIEA (18 mg, 0.135 mmol), DMAP (26 mg, 0.216 mmol) and carbamate 433 (15 mg, 0.027 mmol) in dry CH2C12 (1 mL) under N2 and allowed to stir for 12 hours. Tetrahydro-pyran-4-ylamine hydrochloride salt (11 mg, 0.081 mmol) was added. Then the mixture was stirred at room temperature for another 2 hours. TLC showed the reaction was completed. Water (15 mL) was added and the mixture was extracted with DCM (3 x 15 mL). The combined organic layers were dried over Na2S04, filtered and concentrated to give SW-127 which was purified by preparative HPLC (9.07 mg, 49percent). LCMS (m/z): [M+H]+ 685

Reference： [1]Patent: WO2011/109657,2011,A1 .Location in patent: Page/Page column 437

7
[ 33024-60-1 ]
[ 7693-46-1 ]
[ 932114-22-2 ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; In dichloromethane; at -15 - 0℃; for 2h;	Step 5.1. 4-Nitrophenyl tetrahydro-2ff-pyran-4-ylcarbamateTo a solution of 5.00 g (36.3 mmol) of tetrahydro-2H-pyran- 4-yl-amine hydrochloride (CAS 38041-19-9) in 300 ml of dichloromethane, cooled to -15°C are added portionwise 13.2 g (65.4 mmol) of 4-nitrophenyl chloroformate (CAS 7693- 46-1) and then 12.7 ml (72.7 mmol) of diisopropylethylamine. Stirring is continued at -0°C for 2 hours, and 20 ml of saturated aqueous sodium hydrogen carbonate solution are then added. The organic phase is separated out by settling and dried over sodium sulfate and the solvent is evaporated off under reduced pressure. The residue is purified by chromatography on a column 80 g of silica gel, eluting with a mixture of 20percent acetone in dichloromethane, to give 8.26 g of 4-nitrophenyl tetrahydro-2H-pyran-4-ylcarbamate in the form of a white powder,m.p.: 174-176°CXH NMR (CDC13) delta : 8.25 (d, 2H) ; 7.35 (d, 2H) ; 5.10 (broad d, 1H) ; 4.05 (m d, 2H) ; 3.85 (m, 1H) ; 3.50 (t d, 2H) ; 2.0 (m, 2H) ; 1.60 (m, 2H) ppm.
8.26 g	With N-ethyl-N,N-diisopropylamine; In dichloromethane; at 0℃; for 2h;	To a solution of 5.00 g (36.3 mmol) of tetrahydro-2H-pyran-4-yl-amine hydrochloride (CAS 38041-19-9) in 300 ml of dichloromethane, cooled to -15° C. are added portionwise 13.2 g (65.4 mmol) of 4-nitrophenyl chloroformate (CAS 7693-46-1) and then 12.7 ml (72.7 mmol) of diisopropylethylamine. Stirring is continued at -0° C. for 2 hours, and 20 ml of saturated aqueous sodium hydrogen carbonate solution are then added. The organic phase is separated out by settling and dried over sodium sulfate and the solvent is evaporated off under reduced pressure. The residue is purified by chromatography on a column 80 g of silica gel, eluting with a mixture of 20percent acetone in dichloromethane, to give 8.26 g of 4-nitrophenyl tetrahydro-2H-pyran-4-ylcarbamate in the form of a white powder. m.p.: 174-176° C. 1H NMR (CDCl3) delta: 8.25 (d, 2H); 7.35 (d, 2H); 5.10 (broad d, 1H); 4.05 (m d, 2H); 3.85 (m, 1H); 3.50 (t d, 2H); 2.0 (m, 2H); 1.60 (m, 2H) ppm.

Reference： [1]Patent: WO2011/161537,2011,A2 .Location in patent: Page/Page column 67
[2]Patent: US2013/90340,2013,A1 .Location in patent: Paragraph 0524-0527

8
C₃₄H₅₅NO₅ [ No CAS ]
[ 33024-60-1 ]
[ 7693-46-1 ]
C₄₀H₆₄N₂O₇ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
49%		[001038] Procedure: 4-Nitrophenyl chloro formate (43 mg, 0.216 mmol) was added to DIEA (18 mg, 0.135 mmol), DMAP (26 mg, 0.216 mmol) and carbamate 433 (15 mg, 0.027 mmol) in dry CH2C12 (1 mL) under N2 and allowed to stir for 12 hours. Tetrahydro-pyran-4-ylamine hydrochloride salt (11 mg, 0.081 mmol) was added. Then the mixture was stirred at room temperature for another 2 hours. TLC showed the reaction was completed. Water (15 mL) was added and the mixture was extracted with DCM (3 x 15 mL). The combined organic layers were dried over Na2SC>4, filtered and concentrated to give SW-127 which was purified by preparative HPLC (9.07 mg, 49percent). LCMS (m z): [M+H]+ 685
49%		[001038] Procedure: 4-Nitrophenyl chloro formate (43 mg, 0.216 mmol) was added to DIEA (18 mg, 0.135 mmol), DMAP (26 mg, 0.216 mmol) and carbamate 433 (15 mg, 0.027 mmol) in dry CH2C12 (1 mL) under N2 and allowed to stir for 12 hours. Tetrahydro-pyran-4-ylamine hydrochloride salt (11 mg, 0.081 mmol) was added. Then the mixture was stirred at room temperature for another 2 hours. TLC showed the reaction was completed. Water (15 mL) was added and the mixture was extracted with DCM (3 x 15 mL). The combined organic layers were dried over Na2SC>4, filtered and concentrated to give SW-127 which was purified by preparative HPLC (9.07 mg, 49percent). LCMS (m z): [M+H]+ 685

Reference： [1]Patent: WO2013/36684,2013,A1 .Location in patent: Paragraph 001034
[2]Patent: WO2013/36684,2013,A1 .Location in patent: Paragraph 001034

9
4-((1H-indol-3-yl)methyl)-3-ethylaniline [ No CAS ]
[ 7693-46-1 ]
[ 192130-34-0 ]
tert-butyl 4-(2-(3-(4-((1H-indol-3-yl)methyl)-3-ethylphenyl)ureido)ethyl)piperazine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
80%		Example 5: l-(4-((lH-Indo -3-yl)methyl)-3-ethylphenyl)-3-(2-(piperazin-l-yl)ethyl)urea [00109] Step 1. To a solution of 4-((lH-indol-3-yl)methyl)-3-ethylaniline (0.8 g, 3.2 mmol) and 4-nitrophenyl carbonochloridate (0.64 g, 3.2 mmol) in THF was added diisopropylethylamine (0.4 g, 16 mL, 3.2 mmol) at 25 °C and the resulting solution was stirred for 30 min. Then iert-butyl 4-(2-aminoethyl)piperazine-l-carboxylate (1.5 g, 6.4 mmol) was added to the above solution. The resulting mixture was stirred at 25 °C for 12 h. The mixture was concentrated and purified by preparative HPLC to give iert-butyl 4-(2-(3-(4-((lH-indol-3- yl)methyl)-3-ethylphenyl)ureido)ethyl)piperazine-l-carboxylate (1.3 g, 80percent) as a white solid. 1H NMR (400 MHz, CDC13) delta: 1.16-1.18 (t, 3H), 1.46 (s, 9H), 2.36-2.38 (m, 4H), 2.49-2.52 (t, 2H), 2.64-2.69 (q, 2H), 3.31-3.37 (m, 6H), 4.06 (s, 2H), 5.36 (s, IH), 6.66 (s, IH), 7.01-7.08 (m, IH), 7.12-7.35 (m, 3H), 7.35-7.37 (d, J = 8.0 Hz, IH), 7.54-7.56 (d, J = 8.0 Hz, IH), 8.11 (s, IH).

Reference： [1]Patent: WO2013/148365,2013,A1 .Location in patent: Paragraph 00109

10
[ 7693-46-1 ]
[ 75-31-0 ]
[ 302348-51-2 ]
isopropyl-carbamic acid 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyl ester [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		To a solution of <strong>[302348-51-2][4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-methanol</strong> (2.34 g,10 mmol) and pyridine (890 ul, 11 mmol) in THF (50 ml) at rt was added dropwise a solution of 4-nitrophenyl chloroformate (2.22 g, 11 mmol) in THF (10 ml). The reaction mixture was stirred at rt for overnight. The precipitate was removed by filtration. The filtrate was concentrated to give thedesired compound (4.2 g, may contain some pyridine HCI salt).To a solution of above product (400 mg, 1 mmol) in THF (3 ml) was added isopropyl amine(1.5 ml). The mixture was stirred at rt for 3h then concentrated to give the titled compound. LRMS5 (ESI) mjz 320.2 [(M+H)]+, calc'd for C17H26BN04: 319.21

Reference： [1]Patent: WO2013/134219,2013,A1 .Location in patent: Page/Page column 72; 73

11
[ 19748-66-4 ]
[ 7693-46-1 ]
4-nitrophenyl 3-(pyrrolidin-1-yl)propyl carbonate hydrochloride [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
53%	In diethyl ether; at 20℃; for 2h;	To a solution of 4-nitrophenyl chloroformate (596 mg, 2.84 mmol) in diethyl ether (10 mL), a solution of 3-(pyrrolidin-1-yl)propan-1-ol (manufactured by ABCR, Inc., 386 mg, 2.84 mmol) in diethyl ether (10 mL) was added, followed by stirring at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, and the obtained residue was crystallized from ethanol, followed by filtration, whereby Compound VI-3 (498 mg, 53percent) was obtained. 1H-NMR (DMSO-d6) delta: 1.76-1.84 (m, 2H), 1.85-2.00 (m, 4H), 3.11-3.16 (m, 2H), 3.30-3.44 (m, 4H), 3.47 (t, J=6.0 Hz, 2H), 4.77 (br s, 1H), 6.95 (d, J=9.2 Hz, 2H), 8.11 (d, J=9.2 Hz, 2H)

Reference： [1]Patent: US2014/294978,2014,A1 .Location in patent: Paragraph 0192

12
[ 97682-44-5 ]
[ 7693-46-1 ]
C₄₀H₄₁N₅O₁₀ [ No CAS ]

Reference： [1]RSC Advances,2016,vol. 6,p. 12472 - 12478

13
[ 1585-90-6 ]
[ 7693-46-1 ]
2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl (4-nitrophenyl)carbonate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
55%	With N-ethyl-N,N-diisopropylamine; In dichloromethane; at 20℃; for 18h;Inert atmosphere;	To a solution of maleimidoethanol (0.655 mg, 4.64 mM) in dry DCM (5 ml) under Argon wasadded p-nitrophenylchloroformate (1.12 g, 5.56 mM) and DIPEA (1.13 ml, 6.50 mM)respectively. The reaction was allowed to stir at RT for 18 h. TLC analysis (5 percent methanol inmethylene chloride) indicated that the reaction was complete. The reaction mixture was concentrated and purified using combiflash (Si02) column and eluted with 0-100percent EtOAc in petroleum ether to yield pure EC2474 (0.78 g, 55percent). ?H NMR (500 MHz, CDC13): (5 8.28 (d, J,= 9.0 Hz, 2H), 7.41 ((d, J,= 9.0 Hz, 2H)), 6.77 (s, 2H), 4.41 (t, J,= 4.5 Hz, J2= 5.5 Hz, 2H), 3.95 (t, J,= 4.5 Hz, J2= 5.5 Hz, 2H); ?3C NMR (500 MHz, CDC13): (5170.37, 155.40, 152.40,145.59, 134.36, 125.32, 121.99, 66.15, 36.35

Reference： [1]Patent: WO2016/148674,2016,A1 .Location in patent: Page/Page column 145; 146

Recommend Products

Same Skeleton Products

Related Products

Isomers

Technical Information

• Alkyl Halide Occurrence • Benzylic Oxidation • Birch Reduction • Blanc Chloromethylation • Friedel-Crafts Reaction • General Reactivity • Grignard Reaction • Hiyama Cross-Coupling Reaction • Hydrogenolysis of Benzyl Ether • Kinetics of Alkyl Halides • Kumada Cross-Coupling Reaction • Preparation of Alkylbenzene • Reactions of Alkyl Halides with Reducing Metals • Reactions of Amines • Reactions of Benzene and Substituted Benzenes • Stille Coupling • Substitution and Elimination Reactions of Alkyl Halides • Suzuki Coupling • Vilsmeier-Haack Reaction

Historical Records

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 7693-46-1 ] {[proInfo.proName]}

Quality Control of [ 7693-46-1 ]

Related Doc. of [ 7693-46-1 ]

Product Citations Expand+

Product Details of [ 7693-46-1 ]

Calculated chemistry of [ 7693-46-1 ] Expand+

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 7693-46-1 ]

Application In Synthesis of [ 7693-46-1 ]

[ 7693-46-1 ] Synthesis Path-Downstream 1~13

Technical Information

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry